Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ723MR)

This product GTTS-WQ723MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TNFSF13B gene. The antibody can be applied in Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10673
UniProt ID Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ723MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11413MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI-8897
GTTS-WQ8133MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HH1
GTTS-WQ9262MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMMU-130
GTTS-WQ2989MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Angiocept
GTTS-WQ11227MR IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI3902
GTTS-WQ13289MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-06523435
GTTS-WQ1278MR IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABT-414
GTTS-WQ4781MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BR3-Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW